OR WAIT null SECS
June 01, 2008
The current focus on cost-of-goods (COGS) models is underplaying the benefits of disposables technology in biopharmaceutical manufacturing. The best method for accounting for the benefits of reduced and delayed capital expenditures is through the use of NPV analysis.
April 01, 2008
Disposable technologies that mimic the conventional stainless-steel bioreactor will be most readily adopted
February 01, 2008
The use of disposables has changed significantly in the biopharmaceutical industry.